Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amosartan is a fixed-dose combination pharmaceutical drug primarily used for the treatment of hypertension (high blood pressure) and, in some formulations, hyperlipidemia (dyslipidemia). The original formulation combines two active ingredients: amlodipine camsylate (a calcium channel blocker) and losartan potassium (an angiotensin II receptor blocker). This dual mechanism helps relax blood vessels and lower blood pressure by blocking calcium influx into vascular smooth muscle cells and inhibiting the action of angiotensin II on its receptor. Extended formulations such as Amosartan Q add rosuvastatin (a statin for cholesterol reduction), while Amosartan XQ further includes ezetimibe for additional lipid-lowering effects. These combinations are designed to improve medication adherence and provide integrated management of cardiovascular risk factors[2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amosartan.